Search
Our latest white paper emphasizes the potential of preemptive pharmacogenomics (PGx) to transform mental healthcare by enabling personalized and more effective treatment strategies.
Key highlights include:
• Rising mental health medication use—there has been a significant increase in the use of psychotropic medications, particularly post-pandemic
• Challenges in current treatments—clinicians often face difficulties with trial-and-error prescribing, leading to suboptimal treatment and adverse drug events (ADEs)
• Advantages of PGx testing—the Axiom PharmacoFocus Solution offers a comprehensive set of high-evidence ADME variants to generate accurate pharmacogenomic data, which can enhance drug efficacy and safety
• Integration with clinical systems—PGx testing results can be incorporated into clinical decision support systems (CDSS) and electronic health records (EHR) to provide tailored medication recommendations
• Global and clinical support—there is a growing advocacy for PGx testing in mental health for both safety and efficacy, supported by various studies and global health trends
